What's in Hamad Medical Corporation's pipeline?

Hamad Medical Corporation has 26 drugs in our index: 15 marketed, 0 filed, 7 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with Hamad Medical Corporation's portfolio?

Top competitors by shared drug class: National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eye & ENT Hospital of Fudan University, Kasr El Aini Hospital, Merck Sharp & Dohme LLC, University of British Columbia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hamad-medical-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Hamad Medical Corporation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hamad Medical Corporation pipeline: 15 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 7 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bivalirudin Injection	Bivalirudin Injection	marketed
Nebulized Lidocaine	Nebulized Lidocaine	marketed
Treatment 1. Metoclopramide	Treatment 1. Metoclopramide	marketed
Fairhaven Pro for men	Fairhaven Pro for men	marketed
Diclofenac and Paracetamol	Diclofenac and Paracetamol	marketed
Treatment 2 Ondansetron	Treatment 2 Ondansetron	marketed	5-HT3 receptor antagonist	5-HT3 receptor	Oncology, Gastroenterology
TauroLock U 25000	TauroLock U 25000	marketed	Antimicrobial lock solution		Infectious Disease / Critical Care
Dexamethasone Oral	Dexamethasone Oral	marketed	Glucocorticoid (corticosteroid)	Glucocorticoid receptor (GR)	Immunology, Rheumatology, Endocrinology, Oncology (supportive care)
Human albumin	Human albumin	marketed	Plasma volume expander; blood product derivative		Critical Care; Hematology; Trauma
Levobupivacaine and Fentanyl	Levobupivacaine and Fentanyl	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels; mu-opioid receptor	Anesthesia and Pain Management
(TauroLock Hep500)	(TauroLock Hep500)	marketed	Catheter lock solution		Infectious Disease / Vascular Access
Ceftolozane-tazobactam IV	Ceftolozane-tazobactam IV	marketed	Fifth-generation cephalosporin with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases	Infectious Disease

Therapeutic area mix

Anesthesia and Pain Management · 1
Cardiovascular, Neurology · 1
Critical Care; Hematology; Trauma · 1
Diabetes · 1
Hematology/Transfusion Medicine · 1
Immunology · 1
Immunology / Rheumatology · 1
Immunology, Rheumatology, Endocrinology, Oncology (supportive care) · 1
Infectious Disease · 1
Infectious Disease / Critical Care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 2 shared drug classes
Eye & ENT Hospital of Fudan University · 2 shared drug classes
Kasr El Aini Hospital · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
University of British Columbia · 2 shared drug classes
Vanderbilt University Medical Center · 2 shared drug classes
Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hamad Medical Corporation:

Cite this brief

Drug Landscape (2026). Hamad Medical Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hamad-medical-corporation. Accessed 2026-05-17.